“Prevention is better than cure.” In breast cancer, early detection truly can be the cure. Two recent publications underscore just how critical it is to catch breast cancer early, and how powerful screening programs can be when widely adopted. 1. In The BMJ cohort study, nearly 32.1 % of women invited to their first mammography screening did not participate. Over 25 years of follow-up: * Non-participants had a 40 % higher risk of death from breast cancer (9.9 vs 7.0 deaths per 1,000 women) * Non-participants were more likely to receive diagnoses at advanced stages: odds ratio 1.53 for stage III, 3.61 for stage IV vs those who did attend. * The incidence of breast cancer was similar between groups, which suggests that the excess mortality is largely driven by delayed detection, not a higher incidence. This shows that missing that first screening isn’t just a missed appointment but may translate into a long-term survival disadvantage. 2. In Frontiers in Public Health, the authors examine the psychosocial and behavioral determinants influencing women’s screening decisions. Key findings: * In Poland, breast cancer incidence has surged by 60 % over 20 years, and mortality by 30 %. * Despite this rising burden, only 31 % of eligible women underwent mammography in 2024—well below the 70–80 % threshold often posited as necessary for population-level benefit. * Among other determinants, women were significantly more likely to participate if they had prior education about breast cancer, higher health-behavior scores, certain psychosocial attitudes, and emotional support. Combined, these studies send a powerful message: even in contexts where screening is available, uptake, education, psychological factors, and access barriers all influence who benefits. At SurgMark (www.surgmark.com), we believe in doing more than simply making products. We are committed to being part of the solution—to help bridge gaps in early detection and follow-through. Our metal-free breast tissue markers are designed to support clinicians in diagnosis, surgical precision, and longitudinal care, especially in settings where accuracy and safety matter. We stand firm in our mission: to support the global fight against breast cancer with innovation, quality, and purpose. References: 1. https://lnkd.in/eQ9D6uiW 2. https://lnkd.in/ex5WzKuu Dr. Peter A. Meier, MBA Dr. Christine Koenig Thomas Freier Dr. Rivelino Montenegro Frank Drs. med. Schure Frank und Viola Karl Luschmann #breastcancer #surgmark #cancerprevention
SurgMark GmbH
Herstellung medizinischer Geräte
Mehr Sicherheit in der Diagnostik und Therapie von Krebserkrankungen
Info
Wir sind ein Unternehmen, das sich auf innovative Lösungen in Medizintechnik und Biotechnologie spezialisiert hat. Unser Team ist interdisziplinär: Die Gesellschafter kommen aus Medizin, Entwicklung und der Gründerszene. Wir verfügen über langjährige Industrieerfahrung und blicken auf erfolgreiche Gründungen und Verkäufe von Start-ups. Unser Management-Team hat für Investoren mehrfach Exits als Trades Sales realisiert. Auf diese Weise kombinieren wir Fachwissen mit dem Blick für Marktpotentiale.
- Website
-
http://www.surgmark.com
Externer Link zu SurgMark GmbH
- Branche
- Herstellung medizinischer Geräte
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- 22301
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
Orte
-
Primär
Maria-Louisen-Straße 122
22301, Hamburg, DE
Beschäftigte von SurgMark GmbH
Updates
-
Biotech Entrepreneur & PhD Biochemist | Founder in Breast Cancer MedTech | Renewable Energy Startup Leader | Expertise in Strategic Growth & Innovation
Yesterday, I had the pleasure of participating in the 2025 AGM of Anges Quebec. Thanks to the AQ team, it was an amazing event featuring: - Charming and engaging moderation - Inspiring keynote speakers - Panels with rich discussions - Great networking opportunities - Inspirational pitches - Delicious food I appreciate all the effort that went into making this event a success. https://angesquebec.com/en
-
-
-
-
-
+6
-
-
Susan G. Komen’s Commitment to Advancing Breast Cancer Research We are inspired by the recent announcement from Susan G. Komen (world’s leading breast cancer organization), investing nearly $11 million in new research grants to accelerate breakthroughs in breast cancer research. This commitment to supporting innovative science, advancing precision medicine, and addressing health equity is a powerful step forward for everyone impacted by breast cancer. At SurgMark (www.surgmark.com), we are proud to be part of this field. We have just begun commercialization in the US of our first product, SchurSign, a soft, metal-free marker designed to improve the accuracy and comfort of breast cancer localization procedures. Our mission is to support clinicians and patients with advanced, patient-friendly solutions that make a real difference in care. We are encouraged to see foundations like Susan G. Komen leading the way and hope that more organizations will follow by offering grants and support. Together, we can ensure that breast cancer will no longer define or limit anyone’s future. Link to the article: https://lnkd.in/eGAj3gr3 #BreastCancerResearch #Innovation #Healthcare #SurgMark #PatientCare #SchurSign #TissueMarker #BreastCancer Dr. Rivelino Montenegro Dr. Peter A. Meier, MBA Dr. Christine Koenig Thomas Freier Karl Luschmann Frank Drs. med. Schure Frank und Viola Stéphan Toupin Carel Potgieter Wessel Hattingh Dawa Medical LLC.
-
Ultrasound proves its value again in breast cancer detection. A major study from the University of British Columbia, published earlier this year, shows that supplemental ultrasound after a normal mammogram significantly improves cancer detection in women with dense breasts. Among over 5,200 participants, ultrasound doubled the detection rate, identifying early-stage cancers often missed by mammography alone. Read more here: https://lnkd.in/exQA7-4K At SurgMark, we strongly believe in the power of ultrasound, not only for diagnosis but also for safe and precise treatment planning. That’s why we developed SchurSign, a metal-free, soft breast tissue marker that is clearly visible under ultrasound, as well as all standard imaging modalities. More at www.surgmark.com #breastcancer #ultrasound #medicalinnovation #earlydetection #SchurSign #womenhealthcare #cancerdetection #SurgMark Dr. Christine Koenig Dr. Peter A. Meier, MBA Thomas Freier Dr. Rivelino Montenegro Frank Drs. med. Schure Frank und Viola Karl Luschmann
-
International Day of Action for Women’s Health – More Than a Hashtag, A Global Movement May 28th marks a powerful legacy: the International Day of Action for Women’s Health, first launched in 1987 by the Women’s Global Network for Reproductive Rights (WGNRR). What began as a call to spotlight reproductive rights has grown into a global movement demanding comprehensive, accessible, and equitable healthcare for women everywhere. This day is not about awareness alone—it's about accountability. It’s a reminder that millions of women still lack access to early detection, safe technologies, and respectful, patient-centered care. At SurgMark (www.surgmark.com), we take that mission seriously. Our metal-free breast tissue marker, SchurSign™, was developed to support precise, long-term tumor localization by all imaging modalities. Because a woman’s health journey shouldn't be limited by her diagnostic tools. To all clinicians, innovators, and allies working to close the gender gap in medicine: today we honor your work and reaffirm ours. Let’s keep pushing for technologies and policies that prioritize women—not just once a year, but every day. #WomensHealth #InternationalDayOfAction #BreastCancer #MedicalInnovation #Radiology #HealthEquity #SurgMark #SchurSign #WomensRights #EarlyDetection #MRIcompatible #HealthcareForAll Dr. Rivelino Montenegro Thomas Freier Dr. Christine Koenig Dr. Peter A. Meier, MBA Frank Drs. med. Schure Frank und Viola
-
3,500 More Breast Cancers Detected Every Year? The Evidence Is In. A major UK study just published in The Lancet confirms what many clinicians have long suspected: mammography alone isn't enough for women with dense breasts. The BRAID trial—led by Professor Fiona Gilbert at the University of Cambridge—found that: ✅ Contrast-Enhanced Mammography (CEM) and Abbreviated MRI (AB-MRI) can more than triple detection rates in women with very dense breast tissue. ✅ These additional scans could save up to 700 lives annually in the UK alone. ✅ Automated ultrasound (ABUS) also helped, though was less effective. Why does this matter? Dense breast tissue can mask cancers on a mammogram—both appear white, making detection difficult. That’s why a multi-modality imaging approach is not optional—it’s essential. At SurgMark, we’re proud that our SchurSign™ biopsy marker is visible across all modalities, but especially optimized for ultrasound—the modality that continues to grow in relevance for patients with dense tissue. In an era of evolving breast screening, SchurSign™ bridges the gap, ensuring clear visibility whether you're using mammography, MRI, or ultrasound. When accuracy means early detection, the right tools matter more than ever. Let’s build a future where no tumor is missed because of breast density. #BreastCancerAwareness #Radiology #MedicalDevices #Innovation #WomensHealth #Ultrasound #Mammography #MRI #BreastDensity #SurgMark #SchurSign #BRAIDTrial #EarlyDetection Dr. Rivelino Montenegro Dr. Christine Koenig Dr. Peter A. Meier, MBA Frank Drs. med. Schure Frank und Viola Thomas Freier https://lnkd.in/dQHbaBQU
-
SurgMark GmbH hat dies direkt geteilt
It was indeed a very good event. www.surgmark.com
SurgMark at SBI 2025 in Colorado Springs! We had an incredible opportunity to present SurgMark at the Society of Breast Imaging (SBI) 2025 conference in Colorado Springs, USA. It was a privilege to introduce the international breast cancer community to SchurSign, our innovative metal-free, soft tissue marker. Many physicians across the United States have already begun offering SchurSign to their patients, enhancing patient comfort and simplifying imaging procedures. This advancement supports more precise diagnostics and increases the likelihood of successful treatment outcomes. A heartfelt thank you to our dedicated team and to everyone who visited us at the event. Your interest and support inspire us to continue innovating for better breast cancer care. www.surgmark.com #SurgMark #SchurSign #BreastCancer #SBI2025 #MedicalInnovation #PatientCare #Radiology #tissuemarker #CT #MRI #Ultrasound #SBI Thomas Freier Dr. Rivelino Montenegro Dr. Christine Koenig Dr. Peter A. Meier, MBA Frank Drs. med. Schure Frank und Viola
-
-
SurgMark at SBI 2025 in Colorado Springs! We had an incredible opportunity to present SurgMark at the Society of Breast Imaging (SBI) 2025 conference in Colorado Springs, USA. It was a privilege to introduce the international breast cancer community to SchurSign, our innovative metal-free, soft tissue marker. Many physicians across the United States have already begun offering SchurSign to their patients, enhancing patient comfort and simplifying imaging procedures. This advancement supports more precise diagnostics and increases the likelihood of successful treatment outcomes. A heartfelt thank you to our dedicated team and to everyone who visited us at the event. Your interest and support inspire us to continue innovating for better breast cancer care. www.surgmark.com #SurgMark #SchurSign #BreastCancer #SBI2025 #MedicalInnovation #PatientCare #Radiology #tissuemarker #CT #MRI #Ultrasound #SBI Thomas Freier Dr. Rivelino Montenegro Dr. Christine Koenig Dr. Peter A. Meier, MBA Frank Drs. med. Schure Frank und Viola
-
-
🎨 Art. Innovation. Breast Imaging. 💗 At SurgMark GmbH, we believe there is something powerful in the intersection of breast imaging technology and human experience — and nothing captures that better than the beautiful work of Spanish artist Sabela García Cuesta. Together with Guillermo Ansotegui Carnerero, Sabela created a touching video that we’re proud to share. It explores her deeply personal and artistic journey: drawing breasts (“boobs”) from individuals around the world who — for reasons ranging from self-expression to survival — want their bodies to be seen, celebrated, and remembered. This project speaks to the beauty, vulnerability, and cultural taboos surrounding the breast. It also reminds us why we do what we do. That’s why SurgMark will be at the SBI 2025 Symposium in Colorado Springs (starting April 24th), presenting our tissue marker SchurSign — a metal-free, soft, ultrasound-visible, and non-migrating marker, specially designed for patient comfort and clinical precision. Like art, SchurSign was created with intention — to be seen, to last, and to matter. Come visit us at booth #423 to talk breast imaging, technology, and yes — art. A huge thank you to Sabela and Guillermo for letting us share their inspiring work. Watch the video. Feel something. Then come see us at SBI. #SBI2025 #BreastImaging #SchurSign #MedicalInnovation #WomenInArt #PatientComfort #Radiology #ArtAndMedicine #SurgMark #SabelaGarciaCuesta #GuillermoAnsotegui #TissueMarker #BoobsAreArt #BreastCancer #Cancer Dr. Rivelino Montenegro Dr. Christine Koenig Dr. Peter A. Meier, MBA Frank Drs. med. Schure Frank und Viola Thomas Freier Sabela García Cuesta Guillermo Ansotegui Carnerero
-
SurgMark Enters a New Phase – Leadership Transition as Sales Launch in the US March 2025 SurgMark GmbH (www.surgmark.com), the company behind SchurSign, the innovative metal-free tissue marker for breast cancer localization, is proud to announce a new chapter in its journey. With the successful launch of sales in the US, the company is shifting its focus toward market expansion and commercial growth. After six years of dedicated leadership, Dr. Christine König is transitioning from her role as CEO, passing the leadership baton to Dr. Rivelino Montenegro, co-founder of SurgMark. Dr. König has been instrumental in raising capital, navigating the regulatory process, and building strong relationships with the medical community and distributors. She will remain actively involved as a shareholder and board member, continuing to leverage her extensive network to support SurgMark’s global expansion. “We can only thank Dr. König for her incredible work over the past six years,” said Dr. Montenegro, the company’s newly appointed CEO. “As we enter this exciting new phase, we will still need her expertise and network to bring our technology to as many patients as possible.” Dr. Montenegro brings extensive experience in bringing medical innovations to the US, European, South African, and Israeli markets. His leadership will be key in scaling SurgMark’s operations and ensuring that breast cancer patients and physicians worldwide benefit from our tissue marker, designed for superior ultrasound visibility without metal interference. The entire SurgMark team is grateful for Dr. König’s leadership and looks forward to this next phase of growth. For further inquiries or partnership opportunities, please contact: [email protected] #Innovation #BreastCancer #MedicalTechnology #LeadershipTransition #SurgMark Dr. Christine Koenig Dr. Peter A. Meier, MBA Frank Drs. med. Schure Frank und Viola Thomas Freier Dr. Rivelino Montenegro